Polymersome-mediated Cbl-b silencing activates T cells against solid tumors

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• T cell function is crucial for effective cancer immunotherapy.
• Casitas B-lineage lymphoma proto-oncogene b (Cbl-b) acts as an intracellular checkpoint that can inhibit T cell activity.
• Targeting Cbl-b offers a potential strategy to enhance anti-tumor immune responses.

Purpose of the Study:

• To develop and evaluate an in vivo T cell activation strategy by silencing Cbl-b.
• To assess the efficacy of polymersome-delivered siRNA targeting cblb in combating solid tumors.
• To investigate the impact of cblb gene silencing on T cell function and tumor progression.

Main Methods:

• Developed polymersomes for efficient loading and delivery of siRNA targeting cblb.
• Administered polymersome-siRNA complexes in vitro and in vivo to primary T cells and tumor models.
• Assessed cblb gene silencing, IL-2 receptor CD25 expression, T cell exhaustion markers, and tumor progression in B16-F10 and LLC models.

Main Results:

• Successfully silenced cblb gene expression in primary T cells, enhancing CD25 expression and T cell function.
• Demonstrated effective inhibition of tumor progression in both B16-F10 and LLC models.
• Observed increased effector T cells and decreased Treg cells within tumors, alongside increased peripheral effector T cells.

Conclusions:

• Polymersome-mediated cblb gene silencing in T cells is a promising approach for cancer immunotherapy.
• This strategy enhances T cell activation and function, leading to improved anti-tumor capacity.
• The findings support the potential of targeting intracellular checkpoints like Cbl-b to overcome tumor immune evasion.